Table 1.
Patient characteristics
| Characteristics | All | Radical RT group | Salvage RT group | Oligomts RT group |
|---|---|---|---|---|
| Patient groups | ||||
| Patients (n) | 43 | 21 | 17 | 5 |
| Age (years), (range) | 70 (58–84) | 72 (65–81) | 69 (58–84) | 68 (65–71) |
| Gleason score | ||||
| 6–7 | 24 | 14 | 8 | 2 |
| 8–9 | 18 | 7 | 8 | 3 |
| TNM stage | ||||
| Tx | 3 | 2 | 1 | 3 |
| T1-2 | 25 | 9 | 11 | 2 |
| T3-4 | 18 | 10 | 5 | 2 |
| N0/x | 38 | 20 | 16 | 3 |
| N1-2 | 5 | 1 | 1 | 3 |
| M0/x | 41 | 21 | 17 | 2 |
| M1 | 2 | – | – | |
| Initial PSA (ng/ml) median (range) | 28.4 (6.3–530) | 52.3 (11–530) | 10.4 (6.3–21) | 22.6 (6.9–52) |
| PSA pre PSMA-PET/CT (ng/ml) median (range) | 4.34 (0.1–30.6) | 9.4 (0.2–30.6) | 2.8 (0.1–21.8) | 0.8 (0.1–1.9) |
| ADT at time of PET | 27 | 21 | 1 | 5 |
| PSMA-PET/CT revealed metastases (LN, Bones, FR) | 30 | 11 | 15 | 4 |
| Lymph nodes | 10 | 4 | 7 | 1 |
| Bones | 6 | 3 | 1 | 2 |
| Lymph nodes and bones | 5 | 4 | – | 1 |
| FR (FR + nodes) | 6 (1) | – | 6 (1) | – |
PSA, prostate-specific antigen; PSMA, PET/CT prostate-specific membrane antigen positron emission tomography/computed tomography; ADT, androgen deprivation therapy; LNs, lymph nodes; FR,fossa recurrence; RT, radiation therapy; Oligomts, oligometastatic; Salvage RT, post-prostatectomy RT